127 related articles for article (PubMed ID: 35695414)
1. Skeletal Disease Acquisition in Fibrous Dysplasia: Natural History and Indicators of Lesion Progression in Children.
Szymczuk V; Taylor J; Michel Z; Sinaii N; Boyce AM
J Bone Miner Res; 2022 Aug; 37(8):1473-1478. PubMed ID: 35695414
[TBL] [Abstract][Full Text] [Related]
2. Lesion Expansion in Gnathic Fibrous Dysplasia: Natural History, Indicators of Progression, and Response to Bisphosphonates.
Pan KS; Taylor J; Szymczuk V; Boyce AM
J Bone Miner Res; 2023 Oct; 38(10):1465-1471. PubMed ID: 37477421
[TBL] [Abstract][Full Text] [Related]
3. Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.
Geels RES; Meier ME; Saikali A; Tsonaka R; Appelman-Dijkstra NM; Boyce AM
J Bone Miner Res; 2022 Feb; 37(2):236-243. PubMed ID: 34668234
[TBL] [Abstract][Full Text] [Related]
4.
Papadakis GZ; Manikis GC; Karantanas AH; Florenzano P; Bagci U; Marias K; Collins MT; Boyce AM
J Bone Miner Res; 2019 Sep; 34(9):1619-1631. PubMed ID: 31116487
[TBL] [Abstract][Full Text] [Related]
5. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
[TBL] [Abstract][Full Text] [Related]
6. A novel approach for fibrous dysplasia assessment using combined planar and quantitative SPECT/CT analysis of Tc-99m-diphosphonate bone scan in correlation with biological bone turnover markers of disease activity.
Jreige M; Hall N; Becce F; Aubry-Rozier B; Gonzalez Rodriguez E; Schaefer N; Prior JO; Nicod Lalonde M
Front Med (Lausanne); 2022; 9():1050854. PubMed ID: 36507503
[TBL] [Abstract][Full Text] [Related]
7. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.
van der Bruggen W; Hagelstein-Rotman M; de Geus-Oei LF; Smit F; Dijkstra PDS; Appelman-Dijkstra NM; Vriens D
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1527-1537. PubMed ID: 31875244
[TBL] [Abstract][Full Text] [Related]
8. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome.
Hart ES; Kelly MH; Brillante B; Chen CC; Ziran N; Lee JS; Feuillan P; Leet AI; Kushner H; Robey PG; Collins MT
J Bone Miner Res; 2007 Sep; 22(9):1468-74. PubMed ID: 17501668
[TBL] [Abstract][Full Text] [Related]
9. The value of
Zhang L; He Q; Li W; Zhang R
BMC Med Imaging; 2017 Jul; 17(1):46. PubMed ID: 28738834
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
11. The role of radionuclide bone scintigraphy in fibrous dysplasia of bone.
Zhibin Y; Quanyong L; Libo C; Jun Z; Hankui L; Jifang Z; Ruisen Z
Clin Nucl Med; 2004 Mar; 29(3):177-80. PubMed ID: 15162988
[TBL] [Abstract][Full Text] [Related]
12. The role of dual-phase Tc-99m MIBI in the evaluation of potentially operable lesions detected by bone scanning in fibrous dysplasia: a long-term prospective follow-up study.
Ones T; Erol B; Aras M; Dede F; Erdil TY; Inanir S; Turoglu HT
Nucl Med Commun; 2012 Mar; 33(3):288-96. PubMed ID: 22198723
[TBL] [Abstract][Full Text] [Related]
13. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates.
Berglund JA; Tella SH; Tuthill KF; Kim L; Guthrie LC; Paul SM; Stanton R; Collins MT; Boyce AM
J Bone Miner Res; 2018 Sep; 33(9):1641-1648. PubMed ID: 29669167
[TBL] [Abstract][Full Text] [Related]
14. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.
Collins MT; Kushner H; Reynolds JC; Chebli C; Kelly MH; Gupta A; Brillante B; Leet AI; Riminucci M; Robey PG; Bianco P; Wientroub S; Chen CC
J Bone Miner Res; 2005 Feb; 20(2):219-26. PubMed ID: 15647815
[TBL] [Abstract][Full Text] [Related]
15. Fibrous dysplasia in children and its management.
Gun ZH; Arif A; Boyce AM
Curr Opin Endocrinol Diabetes Obes; 2024 Feb; 31(1):60-66. PubMed ID: 38010041
[TBL] [Abstract][Full Text] [Related]
16. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
[TBL] [Abstract][Full Text] [Related]
17. Pathologic hepatic Tc-99m-MDP uptake in polyostotic fibrous dysplasia.
Kekilli E; Yagmur C; Kuzucu A; Soysal O; Cikim AS; Ertem K
Ann Nucl Med; 2004 Oct; 18(7):627-30. PubMed ID: 15586638
[TBL] [Abstract][Full Text] [Related]
18. A rare case of polyostotic fibrous dysplasia assessed by bone scintigraphy with Tc-99m methylene diphosphonate (MDP).
Di Leo C; Ardemagni A; Bestetti A; Tagliabue L; Del Sole A; Conte A; Tarolo GL
Nuklearmedizin; 1999; 38(5):169-71. PubMed ID: 10488486
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
Boyce AM; Kelly MH; Brillante BA; Kushner H; Wientroub S; Riminucci M; Bianco P; Robey PG; Collins MT
J Clin Endocrinol Metab; 2014 Nov; 99(11):4133-40. PubMed ID: 25033066
[TBL] [Abstract][Full Text] [Related]
20. Increasing serum alkaline phosphatase is associated with bone deformity progression for patients with polyostotic fibrous dysplasia.
Wang J; Du Z; Li D; Yang R; XiaodongTang ; Yan T; Guo W
J Orthop Surg Res; 2020 Dec; 15(1):583. PubMed ID: 33272306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
